Christopher James Frankenfield

CIK: 0001988344

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (8.3%)

Position reduction

Option Exercises (M)2 (8.3%)

Derivative conversions

Awards (A)12 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)8 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

XLO

Xilio Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (24 total)

XLO
Xilio Therapeutics, Inc.
Jan 2, 2026
Sale(S)
Direct
7K shares at avg. $0.64$5K
XLO
Xilio Therapeutics, Inc.
Jan 1, 2026
Exercise(M)
Direct
19.4K shares-
XLO
Xilio Therapeutics, Inc.
Dec 31, 2025
Award(A)
Stock Option (right to buy)
Direct
668.8K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
37.3K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
150K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
150K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
300K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
300K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
925K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
155.1K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
155.1K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
23.8K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
23.8K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
37.3K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
45K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
45K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
20K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
20K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Disposition(D)
Stock Option (right to buy)
Direct
117K shares-
XLO
Xilio Therapeutics, Inc.
Nov 21, 2025
Award(A)
Stock Option (right to buy)
Direct
117K shares-
XLO
Xilio Therapeutics, Inc.
Apr 15, 2025
Award(A)
Stock Option (right to buy)
Direct
75K shares-
XLO
Xilio Therapeutics, Inc.
Jan 2, 2025
Sale(S)
Direct
7K shares at avg. $0.98$7K
XLO
Xilio Therapeutics, Inc.
Jan 1, 2025
Exercise(M)
Direct
19.4K shares-
XLO
Xilio Therapeutics, Inc.
Jan 1, 2025
Award(A)
Stock Option (right to buy)
Direct
251K shares-

		Type	Shares	Price		Ownership
Jan 2, 2026	XLO Xilio Therapeutics, Inc.	Sale(S)	7,030	$0.64	$4,522	Direct
Jan 1, 2026	XLO Xilio Therapeutics, Inc.	Exercise(M)	19,375	-	$0	Direct
Dec 31, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	668,789	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	37,296	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	150,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	150,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	300,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	300,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	925,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	155,090	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	155,090	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	23,786	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	23,786	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	37,296	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	45,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	45,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	20,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	20,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	117,000	-	-	Direct
Nov 21, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	117,000	-	-	Direct
Apr 15, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	75,000	-	-	Direct
Jan 2, 2025	XLO Xilio Therapeutics, Inc.	Sale(S)	6,954	$0.98	$6,841	Direct
Jan 1, 2025	XLO Xilio Therapeutics, Inc.	Exercise(M)	19,375	-	$0	Direct
Jan 1, 2025	XLO Xilio Therapeutics, Inc.	Award(A) Stock Option (right to buy)	251,000	-	-	Direct

1-24 of 24 transactions

About Frankenfield Christopher James

Frankenfield Christopher James (SEC CIK 0001988344) files insider reports with the SEC as Chief Financial Officer of Xilio Therapeutics, Inc. (XLO).

Signal8 holds 4 ownership filings by Frankenfield Christopher James, all Form 4s, filed between Jan 3, 2025 and Jan 5, 2026. Those filings report 24 transactions, from Jan 1, 2025 to Jan 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Frankenfield Christopher James's filings is in WALTHAM, MA.

Recent filings by Frankenfield Christopher James

Jan 2, 2026: Open-market sale of XLO shares (Form 4, code S).
Jan 1, 2026: Option exercise of XLO shares (Form 4, code M).
Dec 31, 2025: Grant or award of XLO derivative securities (Form 4, code A).
Nov 21, 2025: Grant or award of XLO derivative securities (Form 4, code A).
Nov 21, 2025: Disposition to issuer transaction of XLO derivative securities (Form 4, code D).

Other insiders filing for Xilio Therapeutics, Inc. (XLO)

Houvras Yariv, CHIEF MEDICAL OFFICER
Bello Akintunde Olatokumbo, Director
Shannon James Samuel, Director
Curran Daniel J., Director
Xu Yuan, Director
ROSS ROBERT W., Director

How to read Form 4 transaction codes